StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

Investment analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Friday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Trading Down 23.2 %

NASDAQ CHEK opened at $1.19 on Friday. Check-Cap has a 12 month low of $0.56 and a 12 month high of $3.45. The firm has a market capitalization of $6.96 million, a P/E ratio of -0.40 and a beta of 0.25. The business has a fifty day simple moving average of $0.97 and a 200 day simple moving average of $1.55.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.